Previous 10 | Next 10 |
Results Affirm Biological Activity, Safety and Tolerability of DM199 Consistent with Porcine KLK1 Product in Asia Early Data Indicate Statistically and Clinically Significant Reduction in UACR seen in IgA Nephropathy and Hypertensive African Americans – a Key Ri...
DiaMedica produced decent stroke data last year for DM199. The company does not have a lot of cash. DMAC presents a speculative investment opportunity. For further details see: DiaMedica: Undercovered Stroke Drug Company With Decent Data
DiaMedica Therapeutics (DMAC) announces that the U.S. FDA has accepted the company’s Investigational New Drug ((IND)) application for a Phase 2/3 trial in Acute Ischemic Stroke ((AIS)) patients.The company said that it plans to proceed with a pivotal Phase 2/3 study of DM199 ...
Initiating ReMEDy2 – Pivotal Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical Company focused on developing novel treatments for neurological disorders and kidney diseas...
DiaMedica Therapeutics Inc. (DMAC) Q1 2021 Earnings Conference Call May 6, 2021 8:00 AM ET Company Participants Rick Pauls - President & Chief Executive Officer Scott Kellen - Chief Financial Officer Harry Alcorn - Chief Medical Officer Conference Call Participants Alexander Nowak - Craig...
DiaMedica Therapeutics (DMAC): Q1 GAAP EPS of -$0.19.Cash, cash equivalents and marketable securities of $23.4MPress Release For further details see: DiaMedica Therapeutics reports Q1 results
Investigational New Drug (IND) Application Submitted for Phase 2/3 AIS Study Plan to Initiate Phase 2/3 AIS Trial in Summer 2021 REDUX Phase 2 Diabetic Kidney Disease Cohort Readout Expected in Q2 2021 Cash Runway Through Mid-2022 ...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its first quarter 2021 financial results will be released after the markets close on Wednesd...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Rick Pauls, President and CEO, will deliver a corporate presentation at B. Riley’...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company will be presenting two abstracts at the National Kidney Foundation (NKF) 2021 Sp...
News, Short Squeeze, Breakout and More Instantly...
DiaMedica Therapeutics Inc. Company Name:
DMAC Stock Symbol:
NASDAQ Market:
DiaMedica Therapeutics Inc. Website:
Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM Central White Paper: The Potential of DM199 to Treat Preeclampsia DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel trea...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced the closing of its previously announced $11.8 million private placement to accredited investors. The Company sold approximatel...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...